Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
基于痘苗的溶瘤免疫疗法 Pexastimogene Devacirepvec 治疗索拉非尼失败后晚期肝细胞癌患者：一项随机多中心 IIb 期试验 (TRAVERSE)
期刊:Oncoimmunology
影响因子:
doi:10.1080/2162402X.2019.1615817
M Moehler, J Heo, H C Lee, W Y Tak, Y Chao, S W Paik, H J Yim, K S Byun, A Baron, G Ungerechts, D Jonker, L Ruo, M Cho, A Kaubisch, H Wege, P Merle, O Ebert, F Habersetzer, J F Blanc, Olivier Rosmorduc, R Lencioni, R Patt, A M Leen, F Foerster, M Homerin, N Stojkowitz, M Lusky, J M Limacher, M Henne
